Background: Variation in response to the most commonly used class of asthma controller medication, inhaled corticosteroids, presents a serious challenge in asthma management, particularly for steroid-resistant patients with little or no response to treatment. Objective: We applied a systems biology approach to primary clinical and genomic data to identify and validate genes that modulate steroid response in asthmatic children. Methods: We selected 104 inhaled corticosteroid-treated asthmatic non-Hispanic white children and determined a steroid responsiveness endophenotype (SRE) using observations of 6 clinical measures over 4 years. We modeled each subject's cellular steroid response using data from a previously published study of immortalized lymphoblastoid cell lines under dexamethasone (DEX) and sham treatment. We integrated SRE with immortalized lymphoblastoid cell line DEX responses and genotypes to build a genome-scale network using the Reverse Engineering, Forward Simulation modeling framework, identifying 7 genes modulating SRE. Results: Three of these genes were functionally validated by using a stable nuclear factor k-light-chain-enhancer of activated B cells luciferase reporter in A549 human lung epithelial cells, IL-1b cytokine stimulation, and DEX treatment. By using small interfering RNA transfection, knockdown of family with sequence similarity 129 member A (FAM129A) produced a reduction in steroid treatment response (P < .001).
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Inhaled corticosteroids (ICSs) are the most commonly prescribed medications to control asthma. However, not all patients with asthma respond to these treatments; some have symptoms that are well controlled by ICSs, whereas others require additional or alternative medications. 2, 3 Although asthma is a heterogeneous disease, even among a relatively similar cohort of children with mild-to-moderate asthma, there are noticeable differences in the efficacy of ICSs at maintaining asthma control. 2 Several genetic markers have been found to be associated with the efficacy of ICS therapy, such as glucocorticoid-induced transcript 1 (GLCCI1) 4 and corticotrophin-releasing hormone receptor 1 (CRHR1). 2, 5 Although these variants have fairly large effect sizes, in the case of GLCCI1, a genome-wide association study (GWAS) indicated up to 6% of variation in response to ICS treatment, but attempts at clinical validation have produced mixed results. [6] [7] [8] [9] These findings suggest that additional genes might be important for determining ICS response in asthmatic patients. 10 Although studies reviewed in a recently published systematic review of more than 33 publications of ICS responsiveness have used particular asthma-related outcomes as proxies for ICS response, 11 previously, we demonstrated that a combination of multiple clinical outcomes measures steroid responsiveness with higher accuracy, higher stability across populations, and higher robustness to missing data. 12 We refer to this as the steroid responsiveness endophenotype (SRE), and it is a combination of 6 clinical factors: baseline lung function (FEV 1 ); bronchodilator response (change in FEV 1 after administration of albuterol); frequency of asthma-related emergency department and hospital visits; frequency of supplemental courses of oral corticosteroids required to maintain asthma control; airway hyperreactivity measured by using a methacholine challenge test; and daily symptom diary cards. Integrating these factors provides a more complete picture of the response to ICS treatment, which might manifest differently in distinct patients with asthma and has been shown to measure steroid responsiveness more accurately than any of these clinical factors alone. 12 Genomic systems biology approaches, which are defined as those that take a holistic approach to disease understanding informed by multiple disciplines, genomics, and bioinformatic data sources, 13, 14 have previously been effective at identifying biological processes contributing to the cause of complex genetic diseases. 15, 16 Here we take a systems approach to address the genomics of ICS response in patients with asthma, building on our previous Bayesian network-based methodology of Reverse Engineering, Forward Simulation (REFS) modeling. 17 This method uses patients' genomic and outcome data to identify genes driving the associations of interest, enriching for likely causal importance of such associations. REFS uses Markov chain Monte Carlo sampling to construct a collection of Bayesian networks. This collection of networks is termed an ensemble, and by querying the ensemble as a whole, questions can be answered, such as the following: How do single nucleotide polymorphism (SNPs) and genes interact, and which genes have the greatest effect on patient outcomes?
We hypothesized that it should be possible to integrate the ICS responsiveness signal measured in clinical trial subjects with the dexamethasone (DEX) response signal measured in immortalized lymphoblastoid cell lines (LCLs; LCL DEX response) from those subjects to create an informative steroid response network. Thus we expected to determine network edges that are indicative of interactions in steroid biology. Furthermore, we hypothesized that this integrative network will not just represent steroid biology but that secondary sources of variation in LCL DEX response are due to variation in the donor's genotypes and SRE. Thus we expected to determine network edges indicative of variations in genotypes and SRE if relevant signals were detected with sufficient power and for the first neighbors of SRE to be genes or SNPs that modulate the ICS response.
METHODS
Our study design is shown in Fig 1. We selected a cohort from patients with mild-to-moderate childhood asthma who were receiving ICS therapy in the Childhood Asthma Management Program (CAMP) 18, 19 trial and for whom the LCL DEX response and genotypes were available. These data were filtered and combined in the REFS framework to identify genes associated with SRE. To guard against false-positive results, we carried genes forward for functional validation in human airway epithelial cells, in which we measured the effect of gene knockdown on nuclear factor k-light-chain-enhancer of activated B cells (NF-kB) response to treatment with DEX and IL-1b.
CAMP
CAMP was a randomized clinical trial of the efficacy of long-term daily ICS treatments at managing asthma symptoms and improving lung function. 19 CAMP enrolled 1041 children aged 5 to 12 years with mild-to-moderate persistent asthma over a 23-month period and followed them for an additional 4 years. Recruitment criteria and study characteristics have been described previously. 18, 19 During the original trial, CAMP participants were randomized into 3 treatment arms: budesonide (ICS), nedocromil, or placebo. We used 3 major types of data from selected CAMP participants: clinical data (from which we calculated SRE), genotype SNP data, and transcriptomic profiling from LCLs. CAMP participants were selected for the present study cohort, as described below.
Expression data, preprocessing, and quality control After the main CAMP trial concluded, subjects were followed for at least yearly observation. CAMP participants were recontacted for an additional blood draw roughly 6 years after study conclusion. Of participants randomized to ICS treatment, 161 non-Hispanic white subjects provided blood samples from which CD4 1 lymphocytes were isolated. These samples were immortalized and transcriptomically profiled under 2 treatment conditions: DEX treatment (10 26 mol/ L) and a sham (ethanol) control. After 6 hours, expression levels were measured with the Illumina HumanRef8 v2 BeadChip (Illumina, San Diego, Calif). Beadlevel data were stored by using BeadStudio (Illumina), and arrays that had low detection thresholds or low dynamic ranges were marked as failed. Differential and expression quantitative trait loci analysis of this expression set has been described previously, 20 although we used a different quality control (QC) and filtering process for the present study, as described below.
We used the beadarray package 21 for the R statistical language to read the previously saved bead-level data of passing arrays; to produce QC plots, log 2 -transformed bead-level data, bead-type statistics, and bead summary data; and to perform differential expression analysis. We assembled an expression set of DEX and sham arrays, filtered out low-quality probes based on the R illuminaHumanv2.db annotation package, and quantile normalized the data. We used the Bioconductor limma package 22 to examine the multidimensional scaling (MDS) clustering of all arrays, including replicates. We identified and discarded defective arrays and sample mix-ups. We identified arrays with treatment condition mislabeling and either discarded the array or corrected the label. We created a paired set of arrays by discarding subjects with only 1 treatment condition and remaining replicates in such a way as to favor array pairs on the same chip or processed on the same day. We batch corrected this set by using the sva package ComBat function 23 and examined the MDS plot of DEX-sham differential expression. We identified and removed outliers to produce the final set of paired DEX and sham arrays.
We selected probes for the training set by using the intraclass correlation method provided by the R beadarrayFilter package. 24 We used a cutoff of 0.5 to select probes for which the between-array variability exceeded the withinarray variability. This package and cutoff values have been demonstrated to produce more powerful analysis of differentially expressed genes on a publicly available Illumina spike-in expression set. 25 We selected probes separately for the DEX and sham treatment conditions and, using probes that were informative in both conditions, took the (Log 2 [DEX] 2 Log 2 [sham]) difference to produce the LCL DEX response data for the training set.
SRE phenotype
In this study we used the previously described corticosteroid responsiveness endophenotype model. 12 Briefly, it allows the combination of multiple observations of 6 clinical measures to assess a subject's ICS responsiveness. This results in 1 continuous variable that measures the effectiveness of steroid therapy for an individual subject. A more positive value indicates a stronger response to ICSs. SRE has been shown to produce more accurate measurements of ICS response than individual phenotypes in white replication populations of children and adults with mild to moderately severe asthma and for children of multiple races. 12 We applied it throughout the 4 years of the clinical trial portion of CAMP to produce SRE and its 6 components for each subject.
Genotypes
Genome-wide genotyping was previously performed at the Channing Division of Network Medicine by using Illumina HumanHap 610 bead chips (Illumina, San Diego, Calif). 26 After pruning for minor allele frequency (<5%) and probability of Hardy-Weinberg equilibrium (<0.1%) and removing discordant probes identified by Illumina, 471,851 SNPs remained genotyped among 581 non-Hispanic white CAMP participants in 551 families, with a genotyping rate of 0.998. We imputed missing genotypes by using MaCH. 27 
SNP selection
To identify potentially informative SNPs for REFS modeling, we performed an SRE GWAS within the CAMP Budesonide ICS treatment arm (n 5 172) using the R GenABLE package. 28 We selected 1 sibling from each family for inclusion based on which sibling had LCL DEX response data or randomly if no sibling had response data, excluded subjects with too high autosomal heterozygosity, and excluded markers with a minor allele frequency of less than 1.5%. We performed statistical tests for each SNP's 
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Systems Approach Identifies FAM129A as Asthma Steroid Response Regulator
We used 104 participants of the CAMP clinical trial, all of whom randomized to the budesonide ICS treatment arm. Each was assessed on 6 longitudinal measures of steroid treatment for the duration of the original CAMP trial (4 years) to obtain their SRE values, measuring the effectiveness of ICS therapy at managing asthma. These subjects further provided blood samples that were immortalized and treated with both a steroid, DEX, and sham treatment. LCL DEX response and genome-wide SNPs from these participants were used in the REFS network modeling framework to identify a number of genes that interacted with SRE. Three of these 7 genes were validated in lung epithelial cell lines, and FAM129A was shown to be significantly associated with IL1B during steroid treatment. association with SRE based on an additive SNP model by using the GenABLE qtscore function. 28 We used the R fdrtool package 29 to filter GWAS results by using the Higher Criticism Statistic (function hc.thresh) 30 and a P value threshold of less than .001 to select SNPS for the training set. This was expected to produce a tractable number of SNPs containing mostly GWAS false-positive results from which the REFS modeling system could select significant predictors.
Integrative training set
We selected the cohort of non-Hispanic white CAMP participants from the ICS treatment arm who had (1) computable SRE measures, (2) genotype data, and (3) LCL DEX response.
REFS
We modeled the training set using GNS Healthcare's REFS (GNS Healthcare, Cambridge, Mass) modeling pipeline. This method has been previously described. 17 Briefly, REFS learns directly from data without need for a prespecified hypothesis, producing an ensemble or set of Bayesian networks. Because REFS uses the stochastic Markov chain Monte Carlo 31 and simulated annealing methods, each network in the ensemble is different. The number of networks to be generated is specified as an input parameter. These networks are generated and converged in parallel to produce a representative sample of all possible Bayesian networks that could have generated the observed data.
We configured REFS to model our training set variables as continuous values and to allow each variable to act as an input to or output from any other variable, with the exception of SNP genotypes, which were constrained to act as inputs only. After generation, the ensemble was checked to confirm that the process had converged (see Figs E1 and E2 in this article's Online Repository at www.jacionline.org) and predicted the training data reasonably well.
The REFS ensemble consists of possible network topologies that might have generated the observed data. It is necessary to perform in silico simulations to integrate the predictions of the ensemble and ascertain statistical relevance of individual relationships, as well as to identify functional indirect relationships. Using such simulations, we perturbed all possible input variables and measured the effect on all possible downstream targets.
The stochastic nature of the REFS modeling approach causes variability in results. We performed the REFS modeling step twice, each with an ensemble size of 256 networks, using the same input parameters but different random seeds to limit dependence of our results on a single stochastic simulation.
Interaction network
We created a secondary interaction network to summarize each REFS ensemble. In this network we included a vertex for every training set variable and a directed edge for every downstream target for which REFS in silico simulation produced a P value of less than .05. This is an empiric P value computed by using a permutation-based procedure, 17 and it produced networks potentially containing multiple isolated subgraphs. We stored the REFS statistics characterizing the ensemble and simulation results as edge and vertex attributes. We assembled, manipulated, and plotted the interaction network using the R igraph package. We queried the interaction network to identify SNPs and genes that interact directly or indirectly with SRE. We focused our analysis on the subgraph containing SRE and characterized the size of each interaction network by the size of this SRE subgraph. We examined the immediate vicinity of SRE by selecting vertices within 3 hops of SRE (using R igraph package ego function) and identifying neighborhoods based on community structure using the igraph cluster_walktrap function to find densely connected subgraphs through random walks. We simplified plots of these neighborhoods by removing neighborhoods not containing a first neighbor gene. 
Luciferase assay
Cells were washed with PBS and lysed with Glo Lysis Buffer (Promega, Fitchburg, Wis). Protein concentrations were measured by using a bicinchoninic acid agent (Promega). Luciferase assays were performed with Steady-Glo luciferase agent (Promega). Luminescence was measured by using the Synergy 2 plate reader (BioTek Instruments, Winooski, Vt). Each sample was measured in triplicates. Statistical significance was assessed by using a double-sided t test.
Quantitative real-time PCR
Total RNA was isolated from cells by using QIAshredder and RNeasy kits (Qiagen, Germantown, Md). Oligo(dT)-primed cDNA was prepared from 50 ng of total RNA by using the SuperScript III First-strand Synthesis System (Thermo Fisher). Quantitative real-time PCR was set up in the presence of 0.5 mmol/L primers by using the QuantiTect SYBR Green PCR kit (Qiagen). Quantitative real-time PCR was performed on a StepOne Plus real time PCR machine (Applied Biosystems, Foster City, Calif) and analyzed by using the cycle threshold method. b-Actin was used as an internal control for data normalization. Each sample was measured in triplicates.
Study approval
Written informed consent for CAMP participants was obtained at CAMP enrollment by the child's parent or guardian and again at blood draw for collection of biological materials for the purpose of genetic and genomic investigation. These studies were approved by the Partners Human Research Committee, the institutional review board for Brigham and Women's Hospital.
RESULTS
LCL DEX response
We used bead-level data from 362 previously passed arrays for 151 CAMP non-Hispanic white subjects. MDS clustering 
SNP selection
After selection of subjects and exclusion of markers with low minor allele frequency, our SRE GWAS panel contained 165 subjects (74 female and 91 male subjects) with 471,322 markers.
After SRE GWAS and selection using higher criticism, we retained 360 SNPs (with P < .001) to carry forward to the training set.
Cohort characteristics
After QC (see the Methods section), we identified a cohort of 104 participants with complete genotypes, LCL DEX response, and SRE (Table I ). In the cohort SRE exhibited a reasonably normal distribution (see Fig E5 in this article' s Online Repository at www.jacionline.org) and, with an area under the receiver operating characteristic curve of 0.75, measured ICS responsiveness significantly more accurately than any of the individual clinical measures (area under the receiver operating characteristic curve values, 0.58-0.68; P for difference with SRE of < .001 to .018; see Table E2 in this article's Online Repository at www. jacionline.org). After removing 5 SNPS for which minor allele frequency decreased to less than 0.05 in the cohort population, A plot of the interaction network SRE subgraph taken from the second ensemble of 256 REFs networks is shown. Vertex type is indicated as follows: red star, SRE; blue circle, gene; green square, SNP. In the network genes are seen to play a major role, and SNPs are seen to play a minor role. Symbol size is proportional to the number of edges incident on the vertex. Sizes of the SRE and SNPs are exaggerated by a factor of 3 and 2, respectively, for readability. Vertices are located by using MDS of the network shortest path matrix with the R igraph layout_with_mul-tidimentional function.
J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 5 we finalized the REFS training set with 1 phenotype (SRE), 255 SNPS, and 3732 LCL DEX response genes for 104 subjects. We performed the REFS modeling step twice and produced 2 REFS ensembles of 256 networks each.
Interaction network
After our first hypothesis, we created an interaction network for each of the 2 REFS ensembles. These contained SRE subgraphs with 3319 and 3313 vertices connected to SRE either directly or indirectly using 7958 and 8028 edges, respectively. The second REFS ensemble SRE subgraph contained 3302 (88%) of the training set genes and 10 (2.8%) of the training set SNPs, as shown in Fig 2. We inspected the networks to identify candidate steroid response controller genes in the present analysis, choosing genes that were first-degree neighbors of SRE in either network. Six genes appeared in both interaction networks (Table II) ; that FAF1 appears in some but not all networks is not surprising given the stochastic modeling process and the potentially nascent signals associated with SRE.
Gene neighborhoods from the second REFS ensemble are shown in Fig 3. Table E1 in this article's Online Repository at www.jacionline.org.
As predicted in our second hypothesis, all 7 first-neighbor genes showed significant changes with SRE (P < .05) and high correlation between the predicted expression levels and LCL DEX expression training values (Spearman correlation, 0.657-0.894). We examined the association of LCL DEX response with SRE for these genes and found uncorrected P values of .0004 to .02 (see Fig E7 in this article' s Online Repository at www.jacionline.org).
We performed PubMed literature searches to determine whether these genes had been associated previously with asthma or NF-kB. We found that CRP152, EDARADD, FAF1, and YY1 had a higher number of publications, and FAM129A, FAM174B, and FICD had fewer publications; FAM129A and YY1 were reported to be associated with asthma; and EDARADD and YY1 were reported to be associated with NF-kB.
Resource limits constrained us to limit our cellular validation experiments to 4 genes. We chose EDARADD, FAM129A, FICD, and YY1 to include genes that were better represented in the literature (YY1 and EDARADD), less well represented (FAM129A and FICD), associated with asthma (FAM129A and YY1), and associated with NF-kB (YY1 and EDARADD).
Differential expression analysis
We analyzed differential expression in the training set genes (see Fig E8 in this article' s Online Repository at www.jacionline. org). We found that had we used a typical differential expression cutoff, such as fold change of greater than 2, to select genes for the training set, 6 of the 7 SRE first-neighbor genes would not have been included in the training set and thus would not have been found. Although only a few genes were connected directly to SRE, gene-gene interactions were reported for 96% of genes with a fold change of greater than 2 and 91% of genes with a fold change of less than 2 with P values for differential expression of .05 or less. Interactions were also reported for 87% of the 2682 genes with P values of greater than .05, which would not be considered significant in differential expression analysis (see Table E3 in this article's Online Repository at www.jacionline. org).
NF-kB activation
Our functional validation strategy is based on NF-kB, a master transcription factor that controls the expression of a large number of inflammation factors, including cytokines and chemokines, known to be mediators of asthma. Crucially, NF-kB is a transcription factor central to modulation of glucocorticoidinduced transrepression, a mechanism underlying the antiinflammatory effects of corticosteroids.
32,33 Accordingly, we used NF-kB as a functional readout of the inflammatory response and anti-inflammatory activity. We used A549 human lung epithelial NF-kB-Luc reporter cells for functional validation. We created an inflammatory response with cytokine IL-1b treatment and compared the response with that after IL-1b plus DEX treatment to determine the anti-inflammatory treatment effect of glucocorticoids.
We used targeted siRNA transfection to knockdown the expression of candidate genes. We achieved efficient knockdown of mRNA for FAM129A (Fig 5, A) , EDARADD (see Fig E9, A, in this article's Online Repository at www.jacionline.org), and FICD (see Fig E9, A) . YY1 knockdown failed and is not reported further. Knockdown of the FAM129A gene reduced IL-1b-induced NF-kB activity (Fig 5, B) and, more importantly, produced a moderate but statistically significant (P < .001) reduction in steroid treatment response (Fig 5, C) . EDARADD and FICD knockdown had a slight effect on IL-1b-induced NF-kB activity (see Fig E9, B) but did not alter the effect of DEX (see Fig E9, C) . Post hoc investigation of the 355 SNPs included in REFS and FAM129A revealed no SNPs that were identified as expression quantitative trait loci for FAM129A in Genotype-Tissue Expression data. FAM129A was expressed differentially in asthmatic patients versus healthy control subjects in the Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes (U-BIOPRED) cohort Gene Expression Omnibus data (P 5 5.9 3 10 26 ). 34 
DISCUSSION
We hypothesized that we could identify a network representative of steroid biology using LCL DEX response. Using systems biology, detailed clinical observations, and blood drawn from children with asthma, we identified 7 genes associated with steroid response. A key finding of our study is that FAM129A modulates the in vitro steroid anti-inflammatory response in A549 human lung epithelial cells from the 3 genes successfully tested in knockout experiments. Thus both hypotheses (ie, that the network would represent steroid biology and individual variations in SRE) were confirmed. The direction of effect of FAM129A in our airway epithelial cell model supports FAM129A as augmenting the anti-inflammatory effects of ICSs in asthmatic patients. In addition, we found that the systems biology model helps to ensure the biologic validity of these genes through multiple REFS iterations, resulting in carefully annotated interaction networks.
Our finding that FAM129A modulates steroid response is supported by a study by King et al 35 on glucocorticoid repression of inflammatory genes in A549 cells. They found 34 genes, including FAM129A, that exhibited more than 10-fold induction by IL-1b and significant repression by the addition of DEX at 6 hours. FAM129A mRNA expression was measured at 1, 2, 6, and 18 hours for cells treated with IL-1b, IL-1b plus DEX, DEX alone, or no treatment. FAM129A mRNA expression remained at basal levels at 1 and 2 hours, was repressed to 47% (P < .001) of IL-1b induction level by the addition of DEX at 6 hours, and returned to basal levels at 18 hours independent of IL-1b and/or DEX treatment. Thus IL-1b induced FAM129A expression, and the induction was repressed by DEX. Collectively, our results and those of King et al point to FAM129A's active role in the airway epithelial cell inflammatory response and steroid treatment effect both as controls and controlled variables. This suggests the existence of a FAM129A regulatory circuit playing a central role in airway epithelial cell inflammatory response, where FAM129A seems to promote inflammation but enhance the anti-inflammation effect of DEX. Additionally, FAM129A has been reported as a marker 36 and modulator 37 of thyroid tumors. It is possible that dysregulation of FAM129A leads to cell-cycle abnormalities and aberrant cell growth, which could cause both cancer and airway remodeling.
Our network indicates an interaction between FAM129A product and steroid responsiveness in children with asthma. Other work shows that the FAM129A regulatory circuit observed in airway epithelial cells is active in asthma inflammation and the steroid treatment response: in a study of 12 asthmatic patients, Yick et al 38 found that prednisolone upregulated 85 genes, one of which was FAM129A, in laser-microdissected airway smooth muscle. In a subsequent study, Yick et al 39 found FAM129A to be one of 8 genes exhibiting differential expression in asthmatic patients.
Our study demonstrates how a systems biology model can help identify biologically relevant genes. Such methods have been applied successfully in other studies of lung disease, identifying gene groups associated with asthma control, 40 gene groups associated with severity of chronic obstructive pulmonary disease, 41 and GAB1 as a novel regulator of the inflammatory response in asthmatic patients. 42 Furthermore, the REFS modeling technique has been effective in a variety of other applications, including novel gene identification for rheumatoid arthritis, 17 type 2 diabetes, 43 and breast cancer. 44 Interestingly, GLCCI1, 4 a GWAS hit found in CAMP, was not an SRE first neighbor. This might be related to the different phenotypes used: the GWAS phenotype that identified GLCCI1 was changed in FEV 1 after 4 to 8 weeks of ICS treatment, whereas the phenotype used in the current work, SRE, is a composite of 6 phenotypes and not strongly correlated with FEV 1 . Thus these studies are likely to select different genomic features. CRHR1 2,5 might not have been identified in the current study for similar reasons.
We expected the REFS modeling system to connect genes and SNPs with SRE that would not otherwise be identified by means of traditional differential expression analysis. This is evidenced by the divergence between genes that would be judged important in a differential expression volcano plot (see Fig E8) and the SRE first-neighbor genes we identified. Most genes included in the REFS modeling step were connected or indirectly connected to SRE in the consensus network ensemble (88%, see Table E3 ), most of which would typically be ignored in differential expression analysis. This suggests the potential of the study methodology to extract additional information from existing expression sets.
Our study has several strengths. We used a composite measure of steroid responsiveness, SRE, which allowed us to interrogate a general asthma-related steroid response phenotype. We used a powerful machine-learning and network-based methodology to identify interactions of several genes with SRE in children with mild-to-moderate asthma. We also provided strong functional evidence that FAM129A is an in vitro modulator of steroid efficacy in subsiding inflammation.
Our study also has several limitations. We had a modest sample size of LCLs. Although we did identify some steroid-response genes, we might have been able to identify more whether the LCLs were stimulated with an inflammatory cytokine in addition to DEX. This might provide a more direct readout of the cellular response to steroid remediation of inflammation. Alternatively, steroids other than DEX could be investigated; although our previous work has shown that clinical response to various ICSs is distributionally similar, 5, 12 there might be differences in cellular response by the type of ICS used.
Additionally, our study might have been weakened because LCLs were derived from blood drawn 6 years past the conclusion of the CAMP study trial rather than during the trial. There are also parameters of the REFS methodology that could be altered, with the possibility of identifying additional steroid-response modulating genes by, for example, altering the P value threshold (P < .05) for edge inclusion in REFS networks. Although our previous work on SRE showed no significant age effect within the CAMP population and validated its accuracy in heterogeneous study populations with mean ages from 9 to 34 years, 12 it is possible that steroid responsiveness changed somewhat from CAMP enrollment to blood draw.
Additionally, testing of the in vitro steroid response in primary epithelial cells instead of the A549 human epithelial cell line could improve the relevance of validation results. The observed This shows that action of FAM129A on SRE is likely mediated by a number of genes, including AGO2 and RAD21. Edge width is proportional to and edges are labeled with the proportion of the 256 ensemble networks that contain the edge. Vertex type is indicated as follows: red star, SRE; circle, gene. The FAM129A neighborhood, as indicated by the colored outline, was determined as described in the Methods section. Symbol size is proportional to the number of all interaction network edges incident on the vertex, some of which might not be shown. The figure was plotted by using the same layout as in Fig 2. change in steroid response with FAM129A knockdown was small, and a change to primary cells might result in an increased observed effect size because A549 cells can intact NF-kB activation and glucocorticoid receptor-responsive mechanisms and thus might underestimate the inflammatory response in asthmatic patients. Therefore Fig 5, C , might underestimate the effect of FAM129A. Further functional validation would also be important, including testing of FAM129A in an independent cohort of children with asthma.
In conclusion, previous findings by others have shown that FAM129A responds to steroid treatment in asthmatic patients and in lung epithelial cells and that FAM129A is differentially expressed in asthmatic patients. We have shown that FAM129A is associated with variation in clinical asthma steroid responsiveness and that FAM129A modulates steroid responsiveness in lung epithelial cells. Further work is needed to validate the other SRE neighbor genes identified by the network (CEP152, FAF1, FAM174B, and YY1). At the cellular level, additional investigations are needed to characterize the FAM129A circuit. At the clinical level, further work is needed to investigate the potential for translation of FAM129A to the management of patients with steroid-resistant asthma. Finally, the relevance of the FAM129A circuit to other inflammatory diseases needs to be investigated.
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Key messages
d FAM129A is a modulator of ICS response in asthmatic patients.
d Steroid response is measured usefully as a combination of asthma control outcomes.
d Systems biology methodologies can identify biologically relevant genes that would go undetected by using traditional analysis. Baseline mean, SRE effect, and P value were produced from REFS all-versus-all simulation, which perturbs every variable and determines the effect on every other variable. Correlations and correlation P values are produced by simulating the maximum likelihood estimates for these genes and comparing with DEX response data. Edges were created in the interaction network for every such effect with a P value of less than .05 (ie, P value above Connected to SRE, Genes that were connected directly or indirectly to SRE in the SRE subgraph of the interaction network; FC, fold change; Not connected, genes that were located in isolated subgraphs (total n 5 28) or not present in the interaction network (total n 5 419).
